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condition was present in only 18 patients (16.2%). Pneumococcal IE
affected a native valve in 93.7% of patients. Left-sided endocarditis
predominated (aortic valve 53.2% and mitral valve 40.5%). The micro-
biological diagnosis was obtained from blood cultures in 84.7% of
cases. In the Spanish cohort, nonsusceptibility to penicillin was detected
in 4.2%. The most common clinical manifestations included fever
(71.2%), a new heart murmur (55%), pneumonia (45.9%), meningitis
(40.5%), and Austrian syndrome (26.1%). Cardiac surgery was per-
formed in 47.7% of patients. The in-hospital mortality rate was 20.7%.
The multivariate analysis revealed the independent risk factors for
mortality to be meningitis (OR, 4.3; 95% CI, 1.4–12.9; P< 0.01).
Valve surgery was protective (OR, 0.1; 95% CI, 0.04–0.4; P< 0.01).
Streptococcus pneumoniae IE is a community-acquired disease that
mainly affects native aortic valves. Half of the cases in the present study
had concomitant pneumonia, and a considerable number developed
meningitis. Mortality was high, mainly in patients with central nervous
system (CNS) involvement. Surgery was protective.
(Medicine 94(39):e1562)
Abbreviations: CLSI = Clinical & Laboratory Standards Institute,
CNS = central nervous system, COPD = chronic obstructive
pulmonary disease, GAMES = Grupo de apoyo al manejo de la
endocarditis, HIV = human immunodeficiency virus, ICE =
International Collaboration on Endocarditis study group, IE =
infectious endocarditis, IPD = invasive pneumococcal disease, MIC
= minimum inhibitory concentration, PIE = pneumococcal
infectious endocarditis.
INTRODUCTION
I nvasive pneumococcal disease (IPD) remains a major healthproblem that affects 20 to 35,000 patients per year in the USA
and Europe and causes 3500 to 5800 related deaths.1,2
Streptococcus pneumoniae was responsible for 15% of all
cases of IE in the preantibiotic era,3,4 whereas in the 1980 to
1990s prevalence was <3%.3,5 However, recent data on the
incidence of pneumococcal IE (PIE) are lacking.
Diagnosis, treatment, and outcome have improved during
the last 15 years, thanks to routine immunization, new rapid
molecular and imaging techniques, new cutoff minimum inhibi-
tory concentration (MIC) criteria for penicillin sensitivity, and
multidisciplinary management6.
Most major studies on PIE were published before the year
2000.The objectives of this study were to analyze the epide-
miology and characteristics of PIE in a large prospective multi-
center series and to review cases of PIE reported during the last
14 years.
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MATERIAL AND METHODS
Setting and Study Design
We used the database of GAMES (Grupo de Apoyo al
Manejo de la EndocarditiS), which is a prospective Spanish
registry of consecutive patients with IE defined according to the
modified Duke criteria7 diagnosed between January 1, 2008 and
December 31, 2013 in 27 Spanish hospitals (n¼ 2539). Multi-
disciplinary teams completed a standardized case report form.
Regional and local (Comite´ E´tico de Investigacio´n Clı´nica
Hospital General Universitario Gregorio Maran˜o´n - A´rea 1)
ethics committees approved the study, and patients gave their
informed consent. The follow-up period lasted 1 year.
In order to increase the number of cases, we also included 4
patients prospectively recruited in the coordinating center from
2004 to 2008 (n¼ 228). Additionally, the literature was
reviewed for articles in English, French, and Spanish published
from 2000 to 2013 using the medical subject headings ‘‘Strep-
tococcus pneumoniae endocarditis’’, ‘‘pneumococcal endocar-
ditis’’, and ‘‘pneumococcus endocarditis’’. We also searched
reference lists to identify additional reports of S. pneumoniae
endocarditis. If necessary, the authors were contacted in order to
obtain additional information. Cases with insufficient clinical
information were excluded from this analysis. All cases
recorded during the study period (2000–2013) were included
in a database for statistical analysis.
Diagnosis of IE was based on the Duke criteria combined
with identification of S. pneumoniae in blood and/or in valve
tissue. Identification was based on traditional microbiologic
cultures or molecular techniques.
The IE episode was considered community-acquired or
health care associated based on the classification of the Inter-
national Collaboration on Endocarditis study group (ICE).8
Predisposing conditions for IE were registered, including
previous valve disease, previous valve replacement, and pre-
sence of intracavitary devices, including pacemakers and
implantable cardioverter defibrillators. Mortality during hospi-
talization and mortality after follow-up was recorded. The new
values introduced in 2008 by the Clinical & Laboratory Stan-
dards Institute (CLSI) were used to determine susceptibility to
de Egea et alpenicillin and cefotaxime in the Spanish cohort.9 In the cases
from the literature, when MIC values were not provided, the
published susceptibility (resistant or susceptible) was accepted.
Statistical Analysis
We calculated the incidence of S. pneumoniae endocarditis
as the number of episodes detected each year divided by the
number of inhabitants in the hospital catchment area (in hun-
dreds of thousands) and by the number of hospital admissions
(in thousands).
The statistical analysis was carried out using SPSS 15.0
(SPSS, Chicago, IL). In the univariate analysis, categorical
variables were compared using the chi-square test or the Fish-
er’s exact test. Non-normally distributed continuous variables
were compared using the t test, and normally distributed
variables were compared using the t test or analysis of variance.
In order to assess potential changes in the characteristics of
pneumococcal endocarditis, we compared cases from the Span-
ish cohort with cases collected from the literature review.
Independent factors related to in-hospital mortality were also
assessed using a backwards logistic regression model adjusted
for sex, meningitis (yes vs no), and surgical treatment for the
endocarditis episode (yes vs no).
2 | www.md-journal.comRESULTS
Epidemiology
We analyzed 111 patients with PIE: 24 cases from the
Spanish GAMES cohort (Table 1) and 87 from the literature
published between 2000 and 2013.4,10–70 We excluded cases
diagnosed before 20006,22,26,62,71,72 and cases for which clinical
information was insufficient.73–79
Streptococcus pneumoniae was identified in 24 cases,
namely, 0.86% of the 2539 IE episodes registered in the
GAMES cohort.
Epidemiological Characteristics
The epidemiological characteristics of the 111 patients and
the comparison between the Spanish series and the cases from
the literature are shown in Table 2. Median age was 51 years
(IQR, 26–63) and 71 patients were men (64%). All but 4
episodes (3.6%) were community acquired. The most common
underlying condition was liver disease (27.9%), followed by
immunosuppression (10.8%) and splenectomy or asplenia
(8.1%). A predisposing heart condition was present in 20
patients (18%): 11 with congenital heart disease, 8 with
previous valve disease (2 prosthetic valves), and 1 patient with
a previous history of IE and valve replacement. Patients from
the Spanish cohort were significantly older than those from the
literature, with a median age of 57 (50–69) versus 47 (15–61)
years (P 0.001), and more frequently had previous liver disease
(45.8% vs 23% P 0.03) and predisposing heart valve conditions
(27.3% vs 2.4% P 0.001).
Clinical Presentation
Considering all cases, the most prevalent clinical mani-
festations were fever (71.2%), new heart murmurs (55%), and
vascular phenomena that were only present in 5 patients (4.5%):
2 with disseminated petechiae, 1 with Osler nodes and Janeway
lesions, 1 with subconjunctival hemorrhage and Roth spots, and
1 case with splinter hemorrhages. At diagnosis of endocarditis,
42% of patients presented concomitant pneumonia and 40.5%
presented meningitis. Complete Austrian syndrome (endocar-
ditis, meningitis, and pneumonia) was present in 29 patients
(26.1%) (Table 2). PIE was predominantly left-sided (aortic
valve in 53.2% and mitral valve in 40.5%) and involved a native
valve in 93.7% of cases.
The Spanish cohort more commonly presented prosthetic
valve endocarditis than the cases collected from the literature
(16.7% vs 3.4%, P 0.03).
Diagnostic Methods
Considering the whole series, S. pneumoniae was recov-
ered from blood cultures in 84.7% of the patients and from other
cultures in 73.3% of the cases where data were available.
Cerebrospinal fluid was positive in 33.3% and valve cultures
in 21.2% (Table 3).
Data regarding molecular techniques performed on valve
tissue were available for 9 patients of the 24 cases from the
Spanish cohort; the results were positive for S. pneumoniae for
all of them.
Furthermore, in the Spanish cases, antimicrobial suscepti-
bility was analyzed using the new cutoffs introduced in 2008,
whereas in most reports from the literature, MIC values were
not included. Taking this characteristic limitation of retrospec-
Medicine  Volume 94, Number 39, October 2015tive data into account, penicillin nonsusceptibility rates were
4.2% in the Spanish cohort and 25.9% in the literature
(P¼ 0.05).
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TABLE 2. Demographic and Clinical Characteristics of 111 Patients With Streptococcus pneumoniae Endocarditis
Characteristics Total Cohort N¼ 111 (%) Spanish Cohort n¼ 24 Literature Review n¼ 87 P
Age (median, IQR) 51 (26–63) 57 (50–69) 47 (15–61) 0.001
Sex
Male 71 (64) 18 (75) 53 (60.9) 0.2
Underlying medical condition
Liver disease 31 (27.9) 11 (45.8) 20 (23) 0.03
Alcoholism 22 (19.8) 6 (25) 16 (20.5)
Chronic hepatitis C 5 (4.5) 3 (12.5) 2 (2.3)
Others 3 (2.7) 2 (8.3) 1 (1.1)
Immunosuppression 12 (10.8) 3 (12.5) 9 (11.5) 1
HIV/AIDS 6 (5.4) 1 (4.3) 5 (6)
Malignancy 4 (3.6) 1 (4.3) 3 (3.6)
Solid organ transplantation 1 (0.9) 0 (0) 1 (1.1)
Splenectomy or asplenia 9 (8.1) 0 (0) 9 (11.7) 0.1
COPD 8 (7.2) 4 (16.7) 4 (5.1) 0.08
Intravenous drug use 4 (3.6) 2 (8.3) 2 (2.6) 0.2
Previous heart disease 20 (18) 6 (25.0) 14 (16) 0.2
Congenital heart disease 11 (9.9) 0 (0) 11 (12.9) 0.1
Valve disease 8 (7.2) 6 (27.3) 2 (2.4) 0.001
Previous endocarditis 6 (5.4) 1 (4.2) 5 (6.4) 1
Clinical manifestations
Fever 79 (71.2) 21 (87.5) 58/61 (95,1) 0.6
Heart murmur 61 (55) 17 (77.3) 44/55 (80.0) 0.7
Pneumonia 51 (45.9) 9 (37.5) 42/84 (50.0) 0.3
Meningitis 45 (40.5) 7 (29.2) 38/84 (45.2) 0.2
Austrian syndrome 29 (26.1) 3 (12.5) 26/84 (31.0) 0.1
Vascular phenomena 5 (4.5) 0 (0) 5/62 (8.1) 0.3
Splenomegaly 3 (2.7) 3 (13) 0 (0) 0.02
Type of valve
Native 104 (93.7) 20 (83.3) 84 (96.6) 0.03
Prosthetic 7 (6.3) 4 (16.7) 3 (3.4) 0.03
Affected valve
Aortic 59 (53.2) 14 (58.3) 45 (51.7) 0.6
Mitral 45 (40.5) 10 (41.7) 35 (40.2) 1
Tricuspid 14 (12.6) 3 (12.5) 11 (12.6) 1
More than 1 valve affected 15 (13.5) 3 (12.5) 12 (13.8) 1
Medicine  Volume 94, Number 39, October 2015 Streptococcus Pneumoniae EndocarditisData on capsular serotypes were available for 27 cases
from the whole series and revealed marked diversity. The most
common serotypes were 18C, 23F, and 8 (3 each). Vaccination
data were available for only 13 patients, of whom 4 had been
vaccinated. We could not demonstrate any association between
the serotype and clinical manifestations, complications, or
patient outcome.
For the entire cohort, echocardiography was performed in
98.2% of patients (Table 3). Both of the 2 patients without
echocardiographic data died before diagnosis, which was con-
firmed by autopsy. Major findings included vegetations
(80.2%), valve rupture (18%), and abscesses (8.1%).
Treatment and Outcome
Analyses of the whole series revealed that third-generation
cephalosporins were used in 90.1% of the patients, vancomycin
in 44.1%, and penicillin in 16.2%. Combined therapy was
COPD¼ chronic obstructive pulmonary disease.administered in 62.5% of cases and the most common combi-
nation was third-generation cephalosporins with vancomycin
(15%). Almost half of the patients underwent cardiac surgery
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.for the IE episode (47.7%) (Table 3). There was an indication
for surgery in 67.4% of the patients, and the indications were:
inadequate source of infection control or severe sepsis (17.7%),
heart failure (12.5%), myocardial extension of the infection
(ring abscess, perivalvular tissue involvement, or aortic fistula)
(8.3%), valve rupture or severe valve malfunction (6.3%),
systemic and CNS embolism (3.1%), IE after prosthetic valve
replacement (2%). More than 1 indication was present in 11.5%
of the cases. All of these events represent complications of the
IE episode. Regarding the time of the surgery, 50% of patients
underwent surgery <1 week after the IE diagnostic. We could
not found any differences in the outcome of the patients
regarding time of surgery.
The most common complications were heart failure
(33.3%) and central nervous system embolisms (13.5%).
Non-CNS embolism was reported in 31 patients (27.9%),
including septic arthritis (7.2%) and endophthalmitis (6.3%).Related mortality was 20.7%. As expected, mortality was
higher in the Spanish cohort (33% vs 17%, P¼ 0.09), which
included patients with more severe conditions (older age, more
www.md-journal.com | 5
TABLE 3. Diagnostic Characteristics and Complications of 111 Patients With Pneumococal Endocarditis
Variable Total Cohort N¼ 111 Spanish Cohort n¼ 24 Literature Review n¼ 87 P
Diagnostic characteristics
Positive blood cultures 94 (84.7) 22 (91.7) 72/82 (87.8)

0.7
Other positive cultures 66/90 (73.3)

12 (57.1) 54/69 (78.3)

0.08
CSF 30 (33.3) 5 (25.0) 17 (31.5)
Heart valves 14 (21.2) 5 (41.7) 9 (16.7)
Respiratory tract 11 (12.2) 1 (8.3) 3 (5.6)
Synovial fluid 4 (6.1) 0 (0) 4 (7.4)
Other 6 (9.1) 2 (16.7) 5 (9.3)
Antimicrobial resistance
Nonpenicillin susceptible 15/74 (20.3)

1 (4.2) 14/54 (25.9)

0.05
Noncefotaxime susceptible 3/36 (8.3)

0 (0) 3/22 (13.6)

0.2
Echocardiography 109 (98.2) 24 (100) 85 (97.7) 1
TTE only 27 (24.3) 6 (25.0) 21 (36.8)
TEE only 20 (18.0) 1 (4.2) 19 (33.3)
Both 32 (28.8) 17 (70.8) 15 (26.3)
Technique not specified 30 (27%) 0 (0%) 32 (36.8%)
Ultrasound findings
Vegetation 89 (80.2) 21 (87.5) 68 (78.2) 0.3
Local complication 31 (27.9) 6 (26.1) 25 (34.2) 0.6
Valve rupture 20 (18) 4 (16.7) 16 (18.4) 1
Valve abscess 9 (8.1) 1 (4.2) 8 (9.2) 0.6
Complications
CNS involvement
Meningitis 45 (40.5) 7 (29.2) 38 (43.7) 0.2
Embolism (stroke/abscess) 15 (13.5) 4 (16.7) 11 (12.6) 0.7
Heart failure 37 (33.3) 10 (41.7) 27 (35.5) 0.6
Embolism (excluding CNS) 31 (27.9) 7 (29.2) 24 (27.6) 1
Treatment
Surgical procedure 53 (47.7) 11 (45.8) 42 (48.3) 1
Valve replacement
Aortic 34 (30.6) 8 (33.3) 26 (29.9) 0.8
Mitral 15 (13.5) 3 (12.5) 12 (13.8) 1
Outcome
Death 23 (20.7) 8 (33.3) 15 (17.2) 0.09
nses
s, th
de Egea et al Medicine  Volume 94, Number 39, October 2015underlying diseases, and more frequent prosthetic valve invol-
vement). The risk factors for mortality identified in the uni-
variate analysis were peripheral embolism (47.8% vs 22.7%,
P¼ 0.03), CNS embolism (34.8% vs 8%, P¼ 0.003), meningi-
tis (65.2% vs 34.1%, P¼ 0.009), and Austrian syndrome
(43.5% vs 21.6%, P¼ 0.059), and are summarized in
Table 4. Cardiac surgery was a protective factor against
mortality (17.4% vs 55.7%, P< 0.01). The multivariate analysis
demonstrated that the independent risk factors for mortality
CNS¼ central nervous system, CSF¼ cerebrospinal fluid, TEE¼ tra
Data from the literature were missing for some variables. In those casewere meningitis (OR, 4.3; 95%CI, 1.4–12.9 P< 0.01), whereas
valve surgery was protective (OR, 0.1; 95% CI, 0.04–0.4;
P< 0.01).
DISCUSSION
We performed a 14-year retrospective study of the epide-
miology, clinical manifestations, complications, and outcome
of PIE. PIE affected young adult patients with previous liver
disease and alcoholism, even those with no history of valve
disease. It is more frequent in left-sided valves. Interestingly,
pneumonia was present in half of all cases and Austrian
6 | www.md-journal.comsyndrome in a quarter. Despite advances in modern medicine,
mortality remains high (20.7%), and complications due to valve
dysfunction are common. Almost half of the patients in our
study required valve surgery, and the only risk factor associated
with better survival was early heart surgery.
In a publication of the International Collaboration on
Endocarditis-Prospective Cohort, the prevalence of all types
of streptococcal IE was 6% (excluding viridans group strepto-
cocci and Streptococcus bovis).80 No recent prospective data are
available for PIE. The US Invasive Pneumococcal Disease
(IPD) surveillance report showed 33,500 cases of IPD (10.6/
100,000) and 3500 deaths (1.1/100,000).1 In Europe, according
to the European Centre for Disease Prevention and Control, 26
EU/EEA countries reported 20,843 confirmed cases of IPD in
2011 (5.59/100,000), with 5771 related deaths (10.3%).2
Immunosuppressed patients (solid organ transplant, malig-
nancy, and HIV infection) and patients with specific chronic
disorders (cirrhosis, alcoholism, COPD, and diabetes mellitus)
ophageal echocardiography, TTE¼ transthoracic echocardiography.
e percentage was calculated using the available data as the denominator.have a higher risk of developing IPD. Moreover, several studies
proposed that these factors are even more important than
the specific pneumococcal serotype as determinants of
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Prognostic Factors for 111 Patients With Streptococcus pneumoniae IE (Univariate Analysis)
Variable Alive 88 (79.3%) Dead 23 (20.7%) P
Male 54 (61.4) 17 (73.9) 0.3
Female 34 (38.6) 6 (26.1) 0.3
CNS embolism 7 (8) 8 (34.8) <0.01
Meningitis 30 (34.1) 15 (65.2) <0.01
Surgery 49 (55.7) 4 (17.4) <0.01
Postsurgical complication 9 (18.4) 4 (100) <0.01
Surgery indication 53 (60.2) 7 (30.4) 0.02
Embolism (except CNS) 20 (22.7) 11 (47.8) 0.03
Austrian syndrome 19 (21.6) 10 (43.5) 0.05
Alcoholism 15 (18.5) 7 (33.3) 0.1
Heart failure 26 (32.9) 11 (52.4) 0.1
Pneumonia 37 (43.5) 14 (60.9) 0.1
Aortic valve involvement 44 (50) 15 (65.2) 0.2
Previous valve disease 8 (9.3) 0 (0) 0.3
Previous infective endocarditis 6 (7.5) 0 (0) 0.3
Valve rupture 14 (15.9) 6 (26.1) 0.3
Congenital heart disease 10 (11.5) 1 (4.5) 0.4
Mitral valve involvement 34 (38.6) 11 (47.8) 0.4
Tricuspid valve involvement 10 (11.4) 4 (17.4) 0.4
Intracardiac complication 24 (31.6) 7 (35) 0.7
Pulmonary valve involvement 2 (2.3) 0 (0) 1.0
Immunosuppression 10 (12.2) 2 (10) 1.0
Splenectomy or asplenia 7 (8.8) 2 (9.5) 1.0
Medicine  Volume 94, Number 39, October 2015 Streptococcus Pneumoniae Endocarditisoutcome.3,81,82 In the present series, the most common under-
lying conditions were liver disease due to alcoholism (19.8%)
and immunosuppression (10.8%). Alcoholism is a well-known
predisposing factor for IPD, and its frequency varies from
10.4% to 28.1%.3,83 The reasons for this observation are far
from clear, although potential explanations include malnu-
trition, immunologic defects such as impaired leukocyte che-
motaxis, reticuloendothelial system dysfunction, and risk of
lung aspiration.3,71 Immunosuppression affected 10.8% of the
patients in our study, mainly those with HIV infection (5.4%)
and malignancy (3.6%). Interestingly, a previous study of IPD
in our institution reported a higher percentage of immunosup-
pression (44%), of which the most common causes were HIV
infection (13%) and malignancy (31%).83 These differences
could be explained by the availability of highly active antire-
troviral therapy and good immunological control of HIV-
infected patients in recent years. Finally, previous liver disease
was reported in 27.9% of cases; other authors reported previous
liver disease in 12% of cases.6,83
The classic clinical manifestations of PIE include fever and
acute pneumonia with progressive heart failure, which may be
fatal if appropriate treatment is not administered early.4,74 We
found pneumonia to be the first clinical manifestation of IPD in
almost half of our cases (45.9%). The classic Austrian syndrome
is characterized bymeningitis, pneumonia, and endocarditis due
to S. pneumoniae and is commonly associated with alcoholism.
It was present in 26.1% of our series, and the frequency reported
in the literature varied from 6.7% to 42% of cases.3,71 Austrian
syndrome seems to be a poor prognostic factor and was present
in 43.5% of those who died in our series.
CNS¼ central nervous system.PIE mainly affects native valves, as observed in 93.7% of
the cases we report and 87 to 92% of those reported
elsewhere.6,71 Left-sided endocarditis is the most common
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.presentation, although data on the most commonly affected
valves are contradictory and vary between series. Aortic valve
involvement ranges from 46.7% to 74.4%, and mitral valve
involvement ranges from 31.4% to 56.7%. We found that the
aortic valve was the most commonly involved (53.2%).
Literature from the early 20th century suggested that PIE
tends to form large vegetations that predispose to systemic
embolism.84,85 In our study, almost one-third of patients devel-
oped systemic embolism (13.5% involving the CNS), and
meningitis was present in 40.5%.
Starting in the 1990s, the prevalence of S. pneumoniae
strains with decreased susceptibility to penicillin increased
worldwide. In Spain, it ranged from 18.3% to 59%.86,87 How-
ever, resistance to penicillin has been decreasing in recent years,
possibly owing to the change in the definition of the breakpoint
penicillin MIC in 2008.9 A recent Spanish surveillance study
found 28% prevalence of penicillin-resistant strains when the
CNS infection cutoff MIC of >0.06mg/L was applied; how-
ever, when the cutoff for non-CNS infection was applied (MIC
>2mg/L), the isolates all proved to be susceptible to penicillin.
According to European guidelines, CNS involvement
(meningitis) requires treatment with ceftriaxone or cefotaxime
either alone or in combination with vancomycin.8 In the present
review, we found that 20.3% of strains were classified as
nonsusceptible, although the specific MIC values were not
available in the cases from the literature. In contrast, in the
Spanish cohort, where MIC values were available, we calcu-
lated that with the new cutoffs, nonpenicillin-susceptible strains
only accounted for 4.2%. Nevertheless, we were not able to find
an association between susceptibility to penicillin and clinical
outcome.
Information on capsular serotypes was scarce in the lit-
erature and in our series; the most common serotypes were 18C,
www.md-journal.com | 7
23F, and 8. The correlation between pneumococcal serotypes
and outcome is controversial. Some studies highlight the
relationship between S. pneumoniae serotypes and the risk of
septic shock and higher mortality,82,88 whereas others do not
and conclude that host factors are better determinants of clinical
outcome. The above-mentioned lack of data on capsular ser-
otype from many of the patients included in this series
represents a limitation for the analysis of its impact. Consider-
ing this, we could not demonstrate any association between
capsular serotype and clinical manifestations, complications, or
patient outcome.
As for the epidemiological impact of the pneumococcal
vaccines, numerous studies show a marked decrease in the
prevalence of IPD.89–93 In our series, it was difficult to prove
a correlation between vaccination status and severity of infec-
tion. In Spain, data that would enable us to resolve this question
are lacking. A systematic vaccination register is recommend-
able to evaluate whether vaccination has had an impact in the
incidence of IPD.
Transesophageal echocardiography was performed in 75%
of cases in the Spanish cohort and in 61.8% of cases from the
literature. The major echocardiographic findings were veg-
etations in 80.2% of patients and local complications such as
valve rupture and perivalvular abscess in 26.1%.
Almost half of the cohort underwent valve replacement
for the IE episode. The most frequent indications for surgery in
this series were inadequate control of infection source, severe
sepsis, heart failure, and myocardial extension of the infection.
In the multivariate analysis, this procedure was the only
protective factor against mortality. In the ICE multicenter
study, where 50% of patients underwent surgery, it was also
reported that early surgery improved clinical outcome. Global
mortality for the ICE cohort was 18%.80 Other series presented
PIE-related mortality rates ranging between 24.1% and
62%.3,6,71
In summary, PIE continues to be a severe but very infre-
quent community-acquired infection. It affects patients with
predisposing underlying conditions and can cause compli-
cations, such as meningitis and embolism and severe heart
failure. The new MIC breakpoints for penicillin make high-
dose penicillin or a third-generation cephalosporin the drugs of
choice. Mortality remains high despite early diagnosis and
treatment, which is frequently carried out by multidisciplinary
groups. Early surgery should always be considered.
ACKNOWLEDGMENTS
We would like to thanks Thomas O’Boyle for his help in the
preparation of the manuscript, and Iva´n Ada´n for his help in the
data management.
The preliminary results of this paper were presented at
54th Interscience Conference of Antimicrobial Agents and
Chemotherapy that was held in Washington, DC, on
September 2014.
REFERENCES
1. Active Bacterial Core Surveillance Report, Emerging Infections
Program Network, Streptococcus pneumoniae: CDC; 2013.
2. European Centre for Disease Prevention, Control. Surveillance of
Invasive Bacterial Diseases in Europe. Stockholm: ECDC; 2011.
de Egea et al3. Aronin SI, Mukherjee SK, West JC, et al. Review of pneumococcal
endocarditis in adults in the penicillin era. Clin Infect Dis.
1998;26:165–171.
8 | www.md-journal.com4. Kan B, Ries J, Normark BH, et al. Endocarditis and pericarditis
complicating pneumococcal bacteraemia, with special reference to
the adhesive abilities of pneumococci: results from a prospective
study. Clin Microbiol Infect. 2006;12:338–344.
5. Bayliss RCC, Oakley CM, Somerville W, et al. The microbiology
and pathogenesis of infective endocarditis. Br Heart J. 1983.
6. Martinez E, Miro JM, Almirante B, et al. Effect of penicillin
resistance of Streptococcus pneumoniae on the presentation, prog-
nosis, and treatment of pneumococcal endocarditis in adults. Clin
Infect Dis. 2002;35:130–139.
7. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke
criteria for the diagnosis of infective endocarditis. Clin Infect Dis.
2000;30:633–638.
8. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention,
diagnosis, and treatment of infective endocarditis (new version
2009): the Task Force on the Prevention, Diagnosis, and Treatment
of Infective Endocarditis of the European Society of Cardiology
(ESC). Endorsed by the European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) and the International Society of
Chemotherapy (ISC) for Infection and Cancer. Eur Heart J.
2009;30:2369–2413.
9. Weinstein MP, Klugman KP, Jones RN. Rationale for revised
penicillin susceptibility breakpoints versus Streptococcus pneumo-
niae: coping with antimicrobial susceptibility in an era of resistance.
Clin Infect Dis. 2009;48:1596–1600.
10. Givner LB, Mason EO Jr, Tan TQ, et al. Pneumococcal endocarditis
in children. Clin Infect Dis. 2004;38:1273–1278.
11. Asbach S, Bode C, Geibel A. A severe case of Austrian syndrome.
J Am Soc Echocardiogr. 2004;17:1213.
12. Akcam FZ, Yayli G, Kaya O, et al. Unusual presentation of infective
endocarditis caused by Streptococcus pneumoniae on native tricuspid
valve. Saudi Med J. 2005;26:334–335.
13. Al-Baradai AA, Baskett RJ, Warren AE, et al. The Ross procedure
for endocarditis in a 4-month-old infant. Ann Thorac Surg.
2002;73:1973–1975.
14. Belvisi V, Del Borgo C, Morelli F, et al. Late onset invasive
pneumococcal disease in a liver transplanted patient: beyond the
Austrian syndrome. Transpl Infect Dis. 2013;15:E111–114.
15. Benes J, Picha D, Kabelkova M, et al. Infective endocarditis caused
by unusual gram-positive pathogens. Folia Microbiol (Praha).
2002;47:737–741.
16. Booker J, Musher D. Sinusitis complicated by dural sinus thrombosis
and Streptococcus pneumoniae endocarditis: a case report and review
of the literature. J Infect. 2007;55:106–110.
17. Bothwell JE, Casey F, Webb CH. Tricuspid valvar endocarditis
caused by penicillin resistant pneumococcus. Cardiol Young.
2001;11:556–558.
18. Butler JC, Lennox JL, McDougal LK, et al. Macrolide-resistant
pneumococcal endocarditis and epidural abscess that develop during
erythromycin therapy. Clin Infect Dis. 2003;36:e19–25.
19. du Cheyron D, Lesage A, Le Page O, et al. Corticosteroids as
adjunctive treatment in Austrian’s syndrome (pneumococcal endocar-
ditis, meningitis, and pneumonia): report of two cases and review of
the literature. J Clin Pathol. 2003;56:879–881.
20. Choi M, Mailman TL. Pneumococcal endocarditis in infants and
children. Pediatr Infect Dis J. 2004;23:166–171.
21. Dalal A, Ahmad H. Austrian syndrome (pneumococcal pneumonia,
meningitis, and endocarditis): a case report. Am J Med Sci.
2008;336:354–355.
Medicine  Volume 94, Number 39, October 201522. Endara A, Corkeron MA, Diqer AM, et al. Pneumococcal aortic
valve endocarditis causing aortopulmonary artery fistula. Ann Thorac
Surg. 2001;72:1737–1738.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
23. Esteva F, Ruiz Macarilla S, Vidal N. A 52-year-old male with
meningitis and pneumococcal sepsis with fatal outcome. Med Clin
(Barc). 2002;119:109–116.
24. Favre G, Remy V, Martinot M, et al. Haematogenous brain abscess
complicating a case of Austrian syndrome. Scand J Infect Dis.
2003;35:275–276.
25. Garcia Ordonez MA, Hierro Martin I, Jimenez Martin JJ, et al.
Fulminant pneumococcal pancarditis and acute myocardial infarction
with cardiac failure. An Med Interna. 2006;23:285–287.
26. Gonzalez-Juanatey C, Testa A, Mayo J, et al. Austrian syndrome:
report of two new cases and literature review. Int J Cardiol.
2006;108:273–275.
27. Hristea A, Nicolae D, Luka AI, et al. Invasive pneumococcal
infections: Austrian syndrome. Rom J Intern Med. 2009;47:93–96.
28. Ishiwada N, Niwa K, Tateno S, et al. Pneumococcal endocarditis in
children: a nationwide survey in Japan. Int J Cardiol. 2008;123:298–
301.
29. Kanakadandi V, Annapureddy N, Agarwal SK, et al. The Austrian
syndrome: a case report and review of the literature. Infection.
2013;41:695–700.
30. Luzzati R, Pinamonti B, Giacomazzi D, et al. Aortic-right atrium
fistula complicating Austrian syndrome: a case report and literature
review. Infez Med. 2007;15:124–128.
31. Mankongpaisarnrung C, Soontrapa S, Nantsupawat T, et al. Renal
infarction as a presentation of Austrian syndrome: thromboembolic
phenomenon of pneumococcal endocarditis. Am J Med Sci.
2012;344:251–254.
32. Midon ME, Goldoni F, Souza SG, et al. Austrian Syndrome: case
report. Arq Bras Cardiol. 2011;97:e50–52.
33. Murillo Valles M. Endocarditis neumoco´cica en nin˜o de 17 meses
previamente sano. Anales de Pediatrı´a. 2007;66:615–618.
34. Novak PG, Isserow S, Gudas V, et al. Transesophageal echocardio-
graphic identification of an aortic root to right atrial fistula in a
patient with acute streptococcal aortic valve bacterial endocarditis. J
Am Soc Echocardiogr. 2003;16:497–498.
35. O’Brien S, Dayer M, Benzimra J, et al. Streptococcus pneumoniae
endocarditis on replacement aortic valve with panopthalmitis and
pseudoabscess. BMJ Case Rep. 20112011.
36. Patra KP, Vanchiere JA, Bocchini JA Jr et al. Endocarditis with
ruptured sinus of Valsalva aneurysm caused by nonvaccine
Streptococcus pneumoniae serotype 21. Tex Heart Inst J. 2012;39:
277–280.
37. Porres-Aguilar M, Flavin NE, Fleming RV, et al. Severe bivalvular
pneumococcal endocarditis and suppurative pericarditis in an immu-
nocompetent patient. Intern Med. 2010;49:321–323.
38. Poulsen JB, Moser C, Espersen K, et al. Austrian syndrome. BMJ
Case Rep. 20112011.
39. Rammeloo L, Hruda J, Sobotka-Plojhar M, et al. Austrian syndrome
in a child-aortic valve endocarditis following pneumococcal menin-
gitis. Int J Cardiol. 2004;94:321–322.
40. Christensen SR, Hansen AB, La Cour M, et al. Bilateral endogenous
bacterial endophthalmitis: a report of four cases. Acta Ophthalmol
Scand. 2004;82 (3 Pt 1):306–310.
41. Siegel M, Timpone J. Penicillin-resistant Streptococcus pneumoniae
endocarditis: a case report and review. Clin Infect Dis. 2001;32:
972–974.
42. Sewlall NH, Tikly M. Invasive pneumococcal infection presenting as
septic arthritis and Austrian-like syndrome involving the tricuspid
valve in a patient with underlying HIV infection. Joint Bone Spine.
Medicine  Volume 94, Number 39, October 20152005;72:86–88.
43. Solorio A. Endocarditis por Streptococcus pneumoniae en un escolar
sano. Anales de Pediatrı´a. 2008;69:366–368.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.44. Subira C, Perez H, Anglada M, et al. Austrian syndrome. Med
Intensiva. 2010;34:155–156.
45. Takabayashi S, Shimpo H, Miyake Y, et al. Performance of the
Fontan procedure using extra-cardiac direct anastomosis on patients
treated for penicillin-resistant Streptococcus pneumoniae endocardi-
tis. Jpn J Thorac Cardiovasc Surg. 2005;53:176–179.
46. Tan M, Armstrong D, Birken C, et al. Bacterial endocarditis in a
child presenting with acute arterial ischemic stroke: should thrombo-
lytic therapy be absolutely contraindicated? Dev Med Child Neurol.
2009;51:151–154.
47. Tanawuttiwat T, Poustinchian B, Treitman A, et al. Pneumococcal
endocarditis with extremely rapid valve destruction in a splenecto-
mized host. J Heart Valve Dis. 2011;20:596–598.
48. Tesfaye H, Lukaskova J, Horinkova J. Sudden renal function
deterioration in an elderly patient on vancomycin therapy for
endocarditis. Cas Lek Cesk. 2012;151:531–534.
49. Trotter JM, Aru G, Fox ER. Austrian triad with sinus of Valsalva
aneurysm and rupture. Ann Thorac Surg. 2006;82:1525–1527.
50. Tsang M, Perera S, Lonn E, et al. Pneumococcal endocarditis
causing valve destruction in the absence of vegetations on transeso-
phageal echocardiography: a series of 3 consecutive cases. Can J
Cardiol. 2013;29:519e517–e519.
51. Uemura L, Grassi NC, Cazarin L. Pneumococcal endocarditis of
subacute evolution. Arq Bras Cardiol. 2001;76:319–322.
52. Valero B. El curso clı´nico agresivo de la endocarditis neumoco´cica.
Revista Clı´nica Espan˜ola. 2007;207:183–186.
53. Velazquez C, Araji O, Barquero JM, et al. Austrian syndrome: a
clinical rarity. Int J Cardiol. 2008;127:e36–e38.
54. Vindas-Cordero JP, Sands M, Sanchez W. Austrian’s triad compli-
cated by suppurative pericarditis and cardiac tamponade: a case
report and review of the literature. Int J Infect Dis. 2009;13:e23–
e25.
55. Voldstedlund M, Pedersen LN, Fuursted K, et al. Different
polymerase chain reaction-based analyses for culture-negative endo-
carditis caused by Streptococcus pneumoniae. Scand J Infect Dis.
2003;35:757–759.
56. Watanabe Y, Taketani Y, Takei Y, et al. Complete heart block
resulting from quadricuspid aortic valve penicillin-resistant pneumo-
coccal endocarditis: a case report. Circ J. 2003;67:275–276.
57. Wenzel AM, Tager FM, Burgos LR, et al. Pneumococcal endocardi-
tis in children: report of a case due to penicillin resistant
Streptococcus pneumoniae. Rev Chilena Infectol. 2006;23:243–246.
58. White B, Diggle M, Todd A, et al. A novel pneumococcus with a
new association. Travel Med Infect Dis. 2011;9:84–87.
59. Wilbring M, Tugtekin SM, Matschke K, et al. Austrian syndrome in
the context of a fulminant pneumococcal native valve endocarditis.
Braz J Infect Dis. 2012;16:486–488.
60. Wong V, Adams J, Jones MI, et al. Pneumococcal endoprosthetic
pulmonary valve endocarditis with crescentic glomerulonephritis and
acute renal failure. Clin Nephrol. 2009;71:318–320.
61. Yusuf J, Ahmad K, Mazumder S, et al. Streptococcus pneumoniae-
associated pneumonia, meningitis, and endocarditis: a case of
Austrian syndrome. J La State Med Soc. 2012;164:324–326.
62. Vandenbos F, Roth S, Montagne N. Endocarditis, meningitis,
pneumopathy and pneumococcal cerebral abscess in an alcoholic
smoker. Rev Mal Respir. 2001;18:545–547.
63. Benillouche-Abitbol E, Chauvat A, Hannoun A, et al. Pneumococcal
endocarditis in native valves. Three original observations in the
adult. Arch Mal Coeur Vaiss. 2002;95:919–923.
Streptococcus Pneumoniae Endocarditis64. Madsen RG, Ladefoged K, Kjaergaard JJ, et al. Endocarditis in
Greenland with special reference to endocarditis caused by Strepto-
coccus pneumoniae. Int J Circumpolar Health. 2009;68:347–353.
www.md-journal.com | 9
65. Atkinson K, Augustine DX, Easaw J. Austrian syndrome: a case
report and review of the literature. BMJ Case Rep. 2009;2009:.
66. Chan JF, Hwang GY, Lamb S, et al. Pneumococcal native aortic
valve endocarditis with mycotic abdominal aortic aneurysm, para-
spinal and iliopsoas abscesses and pneumonia revealing a multiple
myeloma. J Med Microbiol. 2011;60 (Pt 6):851–855.
67. dos Santos VM, Teixeira Vde P, Tironi FA, et al. Austrian
syndrome—autopsy report. Acta Med Austriaca. 2004;31:88–90.
68. Kakogawa J, Orito S, Masuya N, et al. Postpartum maternal
pneumococcal meningitis complicated by endocarditis. Acta Obstet
Gynecol Scand. 2011;90:118–120.
69. Mukerji S, Patel R, Havlichek D Jr. Subdeltoid bursitis: an unusual
presentation of Streptococcus pneumoniae bacterial endocarditis.
South Med J. 2007;100:227–228.
70. Shrestha S, Chintanaboina J, Pancholy S. Recurrent mitral valve
endocarditis caused by Streptococcus pneumoniae in a splenecto-
mized host. Case Rep Infect Dis. 2013;2013:929615.
71. Lefort A, Mainardi JL, Selton-Suty C, et al. Streptococcus pneumo-
niae endocarditis in adults. A multicenter study in France in the era
of penicillin resistance (1991–1998). The Pneumococcal Endocardi-
tis Study Group. Medicine. 2000;79:327–337.
72. Claes K, De Man F, Van de Werf F, et al. Double prosthetic valve
endocarditis caused by Streptococcus pneumoniae. Infection.
2000;28:51–52.
73. Corti ME, Palmieri OJ, Villafane MF, et al. Evaluation of 61
episodes of infective endocarditis in intravenous drug abusers and
human immunodeficiency type-1 virus infection. Rev Argent Micro-
biol. 2004;36:85–87.
74. Heiro M, Helenius H, Hurme S, et al. Short-term and one-year
outcome of infective endocarditis in adult patients treated in a
Finnish teaching hospital during 1980–2004. BMC Infect Dis.
2007;7:78.
75. Lindberg J, Schonheyder HC, Moller JK, et al. Incidence of
pneumococcal endocarditis: a regional health register-based
study in Denmark 1981–1996. Scand J Infect Dis. 2005;37:
417–421.
76. McMahon CJ, Ayres N, Pignatelli RH, et al. Echocardiographic
presentations of endocarditis, and risk factors for rupture of a sinus
of Valsalva in childhood. Cardiol Young. 2003;13:168–172.
77. Munoz P, Sainz J, Rodriguez-Creixems M, et al. Austrian syndrome
caused by highly penicillin-resistant Streptococcus pneumoniae. Clin
Infect Dis. 1999;29:1591–1592.
78. Rueda AM, Serpa JA, Matloobi M, et al. The spectrum of invasive
pneumococcal disease at an adult tertiary care hospital in the early
21st century. Medicine. 2010;89:331–336.
79. Wei HH, Wu KG, Sy LB, et al. Infectious endocarditis in pediatric
patients: analysis of 19 cases presenting at a medical center. J
Microbiol Immunol Infect. 2010;43:430–437.
80. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation,
etiology, and outcome of infective endocarditis in the 21st century:
the International Collaboration on Endocarditis-Prospective Cohort
Study. Arch Intern Med. 2009;169:463–473.
81. Amber IJ, Gilbert EM, Schiffman G, et al. Increased risk of
pneumococcal infections in cardiac transplant recipients. Transplan-
tation. 1990;49:122–125.
82. Naucler P, Darenberg J, Morfeldt E, et al. Contribution of host,
bacterial factors and antibiotic treatment to mortality in adult
patients with bacteraemic pneumococcal pneumonia. Thorax.
2013;68:571–579.
de Egea et al83. Bouza E, Pintado V, Rivera S, et al. Nosocomial bloodstream
infections caused by Streptococcus pneumoniae. Clin Microbiol
Infect. 2005;11:919–924.
10 | www.md-journal.com84. Preble HB. Pneumococcus endocarditis. Am J Med Sci.
1904;128:782–797.
85. Lord FT. Pneumococcus endocarditis. N Engl J Med. 1932;207:767–
768.
86. Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C, et al.
Geographical and ecological analysis of resistance, coresistance, and
coupled resistance to antimicrobials in respiratory pathogenic
bacteria in Spain. Antimicrob Agents Chemother. 2005;49:1965–
1972.
87. Garcia-Rey C, Bouza E, Aguilar L, et al. Evolution of penicillin and
erythromycin co-resistance in Streptococcus pneumoniae in Spain.
Int J Antimicrob Agents. 2003;22:541–544.
88. Alanee SR, McGee L, Jackson D, et al. Association of serotypes of
Streptococcus pneumoniae with disease severity and outcome in
adults: an international study. Clin Infect Dis. 2007;45:46–51.
89. Guevara M, Barricarte A, Gil-Setas A, et al. Changing epidemiology
of invasive pneumococcal disease following increased coverage with
the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol
Infect. 2009;15:1013–1019.
90. Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent
pneumococcal conjugate vaccine Streptococcus pneumoniae sero-
types in US adults aged >/¼50 years with community-acquired
pneumonia. J Infect Dis. 2013;208:1813–1820.
91. Picazo J, Duenas J, Ramirez A, et al. Incidence of pediatric invasive
pneumococcal disease in the Island of Majorca (2008–2010), an area
with non-universal vaccination, and estimations of serotype and
children population coverage by available conjugate vaccines. BMC
Infect Dis. 2013;13:503.
92. Hirose TE, Maluf EM, Rodrigues CO. Pneumococcal meningitis:
epidemiological profile pre- and post-introduction of the pneumococ-
cal 10-valent conjugate vaccine. J Pediatr (Rio J). 2014.
93. Picazo J, Ruiz-Contreras J, Casado-Flores J, et al. Expansion of
serotype coverage in the universal pediatric vaccination calendar:
short-term effects on age- and serotype-dependent incidence of
invasive pneumococcal clinical presentations in Madrid, Spain. Clin
Vaccine Immunol. 2013;20:1524–1530.
APPENDIX 1
Members of GAMES: Hospital Costa del Sol, (Mar-
bella): Fernando Ferna´ndez Sa´nchez, Marian Noureddine, Gab-
riel Rosas, Javier de la Torre Lima; Hospital Universitario de
Cruces, (Bilbao): Jose´ Aramendi, Elena Bereciartua, Marı´a
Victoria Boado, Marta Campan˜a La´zaro, Josune Goikoetxea,
Juan Jose´ Goiti, Jose´ Luis Herna´ndez, Jose´ Ramo´n Irureta-
goyena, JosuIrurzun Zuazabal, Leire Lo´pez-Soria, Miguel
Montejo, Pedro Marı´a Pe´rez, Regino Rodrı´guez, Roberto
Voces; Hospital Universitario Virgen de la Victoria,
(Ma´laga): M Victoria Garcı´a Lo´pez, Radka Ivanova Geor-
gieva, Manuel Ma´rquez Solero, Isabel Rodrı´guez Bailo´n, Josefa
Ruiz Morales; Hospital Universitario Donostia-Policlı´nica
Gipuzkoa, (San Sebastia´n): Ana Marı´a Cuende, Toma´s Eche-
verrı´a, Ana Fuerte, Eduardo Gaminde, Miguel A´ngel Goenaga,
Pedro Idı´goras, Jose´ Antonio Iribarren, Alberto Izaguirre Yarza,
Carlos Reviejo; Hospital General Universitario de Alicante,
(Alicante): Rafael Carrasco, Vicente Climent, Patricio Llamas,
Esperanza Merino, Joaquı´n Plazas, Sergio Reus; Complejo
Hospitalario Universitario A Corun˜a Hospital Juan Cana-
lejo, (A Corun˜a): Nemesio A´lvarez, Jose´ Marı´a Bravo-Ferrer,
Marı´a del Mar Carmona, Laura Castelo, Jose´ Cuenca, Pedro
Llinares, Enrique Miguez Rey, Marı´a Rodrı´guezMayo, Dolores
Medicine  Volume 94, Number 39, October 2015Sousa, M Carmen Zu´n˜iga; Complejo Hospitalario de Espe-
cialidades Juan Ramo´n Jime´nez, (Huelva): Francisco Javier
Martı´nez;Hospital Universitario de Canarias, (Canarias): M
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
del Mar Alonso, Beatriz Castro, Da´cil Garcı´a Marrero, M del
Carmen Dura´n, M Antonia Miguel Go´mez, Juan La Calzada,
Ibrahim Nassar; Hospital Regional Universitario Carlos
Haya, (Ma´laga): Antonio Plata Ciezar, Jose´ M Reguera Igle-
sias; Hospital Universitario Central Asturias, (Oviedo): Vı´c-
tor Asensi A´lvarez, Carlos Costas, Jesu´s de la Hera, Jonnathan
Ferna´ndez Sua´rez, Jose´ Manuel Garcı´a Ruiz, Lisardo Iglesias
Fraile, Jose´ Lo´pez Mene´ndez, Pilar Mencia Bajo, Carlos Mor-
ales, Alfonso Moreno Torrico, Carmen Palomo, Begon˜a Paya
Martı´nez, A´ngeles Rodrı´guez, Raquel Rodrı´guez Garcı´a, Maur-
icio Telenti; Hospital Clinic-IDIBAPS, University of Barcelona
(Barcelona): Manuel Almela, Yolanda Armero, Manuel
Azqueta, Merce´ Brunet, Ramo´n Cartan˜a´, Carlos Cervera, Car-
los Falces, Guillermina Fita, David Fuster, Cristina Garcı´a de la
Maria, Jose´ M. Gatell, Jaume Llopis Pe´rez, Francesc Marco,
Carlos A. Mestres, Jose´ M Miro´, Asuncio´n Moreno, Salvador
Ninot, Eduardo Quintana, Carlos Pare´, Juan Manuel Perica´s,
Jose´ L. Pomar, Jose´ Ramı´rez, Irene Rovira, Marta Sitges, Dolors
Soy, Adria´n Te´llez, Jordi Vila; Hospital General Universi-
tario Gregorio Maran˜o´n, (Madrid): Javier Bermejo, Emilio
Bouza, Viviana de Egea, Alia Eworo, Ana Ferna´ndez Cruz, M
Eugenia Garcı´a Leoni, Marcela Gonza´lez del Vecchio, Vı´ctor
Gonza´lez Ramallo, Martha Kestler Herna´ndez, Mercedes
Marı´n, Manuel Martı´nez-Selle´s, M Cruz Mena´rguez, Patricia
Mun˜oz, Cristina Rinco´n Hugo Rodrı´guez-Abella, Marta Rodrı´-
guez-Cre´ixems, Jorge Rodrı´guez Roda, Blanca Pinilla, A´ngel
Pinto, Maricela Valerio, Eduardo Verde Moreno; Hospital
Universitario La Paz, (Madrid): Isabel Antorrena, Mar Mor-
eno, Jose´ Ramo´n Pan˜o, Sandra Rosillo, Marı´a Romero, Araceli
Saldan˜a; Hospital Universitario Marque´s de Valdecilla,
(Santander): Carlos Armin˜anzas Castillo, Ana Arnaiz, Jose´
de Berrazueta, Manuel Cobo Belaustegui, Raquel Dura´n, M
Carmen Farin˜as, Concepcio´n Farin˜as-A´lvarez, Carlos Ferna´n-
Medicine  Volume 94, Number 39, October 2015Rico, Manuel Gutie´rrez-Cuadra Jose´ Gutie´rrez Dı´ez, Rafael
Martı´n Dura´n, Marcos Pajaro´n, Jose´ Antonio Parra, Ramo´n
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Teira, Jesu´s Zarauza; Hospital Universitario Puerta de
Hierro, (Madrid): Pablo Garcı´a Pavı´a, Jesu´s Gonza´lez, Bea-
triz Orden, Antonio Ramos, Elena Rodrı´guez Gonza´lez; Hos-
pital Universitario Ramo´n y Cajal, (Madrid): Tomasa
Centella, Jose´ Manuel Hermida, Jose´ Luis Moya, Pilar Mar-
tı´n-Da´vila, Enrique Navas, Enrique Oliva, Alejandro del Rı´o,
Soledad Ruiz; Hospital Universitario Virgen de las Nieves,
(Granada): Carmen Hidalgo Tenorio; Hospital Universitario
Virgen Macarena, (Sevilla): Antonio de Castro, Marina de
Cueto, Pastora Gallego, Juan Ga´lvez Acebal, Jesu´s Rodrı´guez
Ban˜o; Hospital Universitario Virgen del Rocı´o, (Sevilla):
Arı´stides de Alarco´n, Emilio Garcı´a, Juan Luis Haro, Jose´
Antonio Lepe, Francisco Lo´pez, Rafael Luque; Hospital San
Pedro, (Logron˜o): Luis Javier Alonso, Jose´ Manuel Azcona
Gutie´rrez, Jose´ Ramo´n Blanco, Lara Garcı´a, Jose´ Antonio
Oteo; Hospital de la Santa Creu i Sant Pau, (Barcelona):
Natividad de Benito, Merce´ Gurguı´, Cristina Pacho, Roser
Pericas, Guillem Pons; Complejo Hospitalario Universi-
tario de Santiago de Compostela, (A Corun˜a): M. A´lvarez,
A. L. Ferna´ndez, Amparo Martı´nez, A. Prieto, Benito Reg-
ueiro, E. Tijeira, Marino Vega; Hospital Santiago Apo´stol,
(Vitoria): Andre´s Canut Blasco, Jose´ Cordo Mollar, Juan
Carlos Gainzarain Arana, Oscar Garcı´a Uriarte, Alejandro
Martı´n Lo´pez, Zurin˜e Ortiz de Za´rate, Jose´ Antonio Urturi
Matos; Hospital SAS Lı´nea de la Concepcio´n, (Ca´diz): M
Bele´n Nacle, Antonio Sa´nchez, Luis Vallejo; Hospital Uni-
versitario Virgen de la Arrixaca (Murcia): Jose´ M Arribas
Leal, Elisa Garcı´a Va´zquez, Alicia Herna´ndez Torres, Ana
Bla´zquez, Gonzalo de la Morena Valenzuela; Hospital de
Txagorritxu, (Vitoria): A´ngel Alonso, Javier Aramburu,
Felicitas Elena Calvo, Anai Moreno Rodrı´guez, Paola Tar-
abini-Castellani; Hospital Virgen de la Salud, (Toledo): Eva
Heredero Ga´lvez, Carolina Maicas Bellido, M Antonia
Streptococcus Pneumoniae EndocarditisSepu´lveda; Hospital Rafael Me´ndez, (Lorca-Murcia): Evadez Mazarrasa, Rube´n Go´mez Izquierdo, Claudia Gonza´lez
Cascales Alcolea, Pilar Egea Serrano, Jose´ Joaquı´n Herna´ndez
Roca.
www.md-journal.com | 11
